Pharmacokinetics and Acute Safety of Inhaled Testosterone in Postmenopausal Women

This was a preliminary feasibility study to assess the pharmacokinetics and acute safety of a single dose of orally inhaled testosterone via the AERx system, a novel handheld aerosol delivery system in postmenopausal women. Twelve postmenopausal women stabilized on oral estrogen therapy were treated with a single dose of testosterone (0.1, 0.2, or 0.3 mg) by inhalation. Plasma concentrations of sex steroids were measured between 1 and 360 minutes. Pulmonary and cardiovascular adverse events were monitored. Inhaled testosterone produced a dose‐dependent increase in plasma total and free testosterone. At the highest dose (0.3 mg), total and free testosterone increased from baseline (mean ± SD, 0.6 ± 0.3 nmol/L, 2.5 ± 1.0 pmol/L) to maximum levels of 62.6 ± 20.4 nmol/L (total) and 168.2 ± 50.2 pmol/L (free), occurring 1 to 2 minutes after dosing. A 2‐compartment model best described the free and total testosterone pharmacokinetic profile. Dihydrotestosterone levels were higher than baseline at 60 minutes (P < .0002). Estradiol did not vary, but sex hormone binding globulin and albumin fell. There were no adverse events related to the treatment. Administration of inhaled testosterone is safe and achieves a supraphysiologic “pulse” kinetic profile of total and free testosterone with a rapid return to pretreatment levels.

[1]  D. Schoenfeld,et al.  Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  W. Bagchus,et al.  Pharmacokinetic Study in Women of Three Different Doses of a New Formulation of Oral Testosterone Undecanoate, Andriol Testocaps , 2003, Pharmacotherapy.

[3]  J. Thipphawong,et al.  Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[4]  P. Clauson,et al.  Pulmonary insulin administration using the AERx insulin diabetes system. , 2002, Diabetes technology & therapeutics.

[5]  I. Souter,et al.  Pharmacokinetics of testosterone after percutaneous gel or buccal administration. , 2001, Fertility and sterility.

[6]  H. Teede,et al.  Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  Orman,et al.  Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. , 2000, The New England journal of medicine.

[8]  G. Beall,et al.  Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus. , 2000, The Journal of clinical endocrinology and metabolism.

[9]  C. Bernaards,et al.  Time course of effects of testosterone administration on sexual arousal in women. , 2000, Archives of general psychiatry.

[10]  C. Christiansen,et al.  Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response study , 1999, The Lancet.

[11]  G. Rosano,et al.  Acute anti-ischemic effect of testosterone in men with coronary artery disease. , 1999, Circulation.

[12]  C. Webb,et al.  Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. , 1999, The American journal of cardiology.

[13]  C. Christiansen,et al.  Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. , 1999, Lancet.

[14]  P. Thompson,et al.  The pharmacokinetics of intravenous testosterone in elderly men with coronary artery disease. , 1998, Journal of clinical pharmacology.

[15]  S J Farr,et al.  Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. , 1998, British journal of clinical pharmacology.

[16]  S J Farr,et al.  Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system , 1997, Clinical pharmacology and therapeutics.

[17]  W. Waldhäusl,et al.  Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  J. Hopper,et al.  Sexuality, hormones and the menopausal transition. , 1997, Maturitas.

[19]  Michael P. Hlastala,et al.  Physiology of respiration , 1996 .

[20]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[21]  H. Burger,et al.  Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. , 1995, Maturitas.

[22]  D. Harris,et al.  The physiology of respiration , 1994, Perfusion.

[23]  K. Matthews,et al.  Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. , 1990, Journal of consulting and clinical psychology.

[24]  R. Lobo,et al.  Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. , 1986, American journal of obstetrics and gynecology.

[25]  B. Sherwin,et al.  Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. , 1985, Psychosomatic medicine.

[26]  H. Burger,et al.  The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. , 1984, Maturitas.

[27]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[28]  G. Gordon,et al.  Further study of factors affecting the metabolic clearance rate of testosterone in man. , 1968, The Journal of clinical endocrinology and metabolism.